CD4+CD25+Foxp3+IFNγ+ Treg are immunosuppressive in vitro and increase with intensity of the alloresponse in pretransplant MLC

Transplant Immunology

Volumn 27, Issue 2-3, 2012, Pages 114-121

  Daniel, Volker ^a   Sadeghi, Mahmoud ^a   Wang, Haihao ^a,b   Opelz, Gerhard ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Induced CD4+CD25+Foxp3+IFN + Treg; Poor long term kidney graft outcome; Pretransplant MLC

Indexed keywords

ALLOANTIGEN; CD4 ANTIGEN; CREATININE; GAMMA INTERFERON; INTERLEUKIN 2 RECEPTOR ALPHA; IONOMYCIN; PHORBOL 13 ACETATE 12 MYRISTATE; TRANSCRIPTION FACTOR FOXP3;

ALLOIMMUNITY; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; GRAFT RECIPIENT; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IN VITRO STUDY; KIDNEY TRANSPLANTATION; LYMPHOCYTE PROLIFERATION; MIXED LYMPHOCYTE CULTURE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

ANTIGENS, CD4; CELLS, CULTURED; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNITY, CELLULAR; IMMUNOSUPPRESSION; INTERFERON-GAMMA; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; ISOANTIGENS; KIDNEY TRANSPLANTATION; LYMPHOCYTE COUNT; LYMPHOCYTE CULTURE TEST, MIXED; PERIOPERATIVE PERIOD; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 84868368929     PISSN: 09663274     EISSN: 18785492     Source Type: Journal    
DOI: 10.1016/j.trim.2012.08.003     Document Type: Article

References (46)

1. Sakaguchi S., Wing K., Yamaguchi T. Dynamics of peripheral tolerance and immune regulation mediated by Treg. Eur J Immunol 2009, 39:2331-2336.
2. +CD25-cells to develop suppressive activity: the role of IL-2, TGF-beta, and IL-10. J Immunol 2004, 172:5213-5221.
3. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
4. Stroopinsky D., Avivi I., Rowe J.M., Avigan D., Katz T. Allogeneic induced human FOXP3(+)IFN-gamma(+) T cells exhibit selective suppressive capacity. Eur J Immunol 2009, 39:2703-2715.
5. + T cells. Int Immunol 2008, 20:1041-1055.
6. Hendrikx T.K., van Gurp E.A., Sewgobind V.D., Mol W.M., Schoordijk W., Klepper M., et al. Generation of donor-specific regulatory T-cell function in kidney transplant patients. Transplantation 2009, 87:376-383.
7. Wei B., Baker S., Wieckiewicz J., Wood K.J. IFN-gamma triggered STAT1-PKB/AKT signalling pathway influences the function of alloantigen reactive regulatory T cells. Am J Transplant 2009, 10:69-80.
8. Sawitzki B., Kingsley C.I., Oliveira V., Karim M., Herber M., Wood K.J. IFN-gamma production by alloantigen-reactive regulatory T cells is important for their regulatory function in vivo. J Exp Med 2005, 201:1925-1935.
9. Feng T., Cao A.T., Weaver C.T., Elson C.O., Cong Y. IL-12 Converts Foxp3 + Regulatory T Cells to Foxp3 + IFN-gamma + T Cells with Inhibitory Functions During Induction of Colitis. Gastroenterology 2011, 140:2031-2043.
10. + regulatory T cells that prevent allograft rejection: potential avenues for cellular therapy. Transplantation 2008, 86:578-589.
11. Feng G., Wood K.J., Bushell A. Regulatory T cell enrichment by IFN-gamma conditioning. Methods Mol Biol 2011, 677:281-301.
12. + blood lymphocytes in kidney transplant recipients with good long-term graft outcome. Transpl Int 2008, 21:646-660.
13. + human induced T regulatory cells are induced by interferon-gamma and suppress alloresponses nonspecifically. Hum Immunol 2011, 72:699-707.
14. + induced human Treg are a heterogenous cell population suppressing alloresponses specifically as well as unspecifically. Transpl Int 2011, 24:114.
15. McClymont S.A., Putnam A.L., Lee M.R., Esensten J.H., Liu W., Hulme M.A., et al. Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol 2011, 186:3918-3926.
16. Dominguez-Villar M., Baecher-Allan C.M., Hafler D.A. Identification of T helper type 1-like, Foxp3+ regulatory T cells in human autoimmune disease. Nat Med 2011, 17:673-675.
17. Probst-Kepper M., Geffers R., Kroger A., Viegas N., Erck C., Hecht H.J., et al. GARP: a key receptor controlling FOXP3 in human regulatory T cells. J Cell Mol Med 2009, 13:3343-3357.
18. Perez-Victoria F.J., Bonifacino J.S. Dual roles of the mammalian GARP complex in tethering and SNARE complex assembly at the trans-golgi network. Mol Cell Biol 2009, 29:5251-5263.
19. Battaglia M., Roncarolo M.G. The Tregs' world according to GARP. Eur J Immunol 2009, 39:3296-3300.
20. Stockis J., Colau D., Coulie P.G., Lucas S. Membrane protein GARP is a receptor for latent TGF-beta on the surface of activated human treg. Eur J Immunol 2009, 39:3315-3322.
21. + regulatory T cells. Proc Natl Acad Sci U S A 2009, 106:13445-13450.
22. + regulatory T cells. Proc Natl Acad Sci U S A 2009, 106:13439-13444.
23. Wood K.J., Sawitzki B. Interferon gamma: a crucial role in the function of induced regulatory T cells in vivo. Trends Immunol 2006, 27:183-187.
24. Jukes J.P., Wood K.J., Jones N.D. Bystander activation of iNKT cells occurs during conventional T-cell alloresponses. Am J Transplant 2012, 12:590-599.
25. Opelz G., Dohler B. Effect of human leukocyte antigen compatibility on kidney graft survival: comparative analysis of two decades. Transplantation 2007, 84:137-143.
26. + regulatory T cells. Transplantation 2009, 87:1062-1068.
27. + regulatory T cells. Blood 2011, 118:2342-2350.
28. Kreijveld E., Koenen H.J., van Cranenbroek B., van Rijssen E., Joosten I., Hilbrands L.B. Immunological monitoring of renal transplant recipients to predict acute allograft rejection following the discontinuation of tacrolimus. PLoS One 2008, 3:e2711.
29. Stary G., Klein I., Bauer W., Koszik F., Reininger B., Kohlhofer S., et al. Glucocorticosteroids modify Langerhans cells to produce TGF-beta and expand regulatory T cells. J Immunol 2011, 186:103-112.
30. Long S.A., Buckner J.H. Combination of rapamycin and IL-2 increases de novo induction of human CD4(+)CD25(+)FOXP3(+) T cells. J Autoimmun 2008, 30:293-302.
31. Jimeno R., Leceta J., Martinez C., Gutierrez-Canas I., Perez-Garcia S., Carrion M., et al. Effect of VIP on the balance between cytokines and master regulators of activated helper T cells. Immunol Cell Biol 2012, 90:178-186.
32. Tsun A., Chen Z., Li B. Romance of the three kingdoms: RORgammat allies with HIF1alpha against FoxP3 in regulating T cell metabolism and differentiation. Protein Cell 2011, 2:778-781.
33. Wang X., Szymczak-Workman A.L., Gravano D.M., Workman C.J., Green D.R., Vignali D.A. Preferential control of induced regulatory T cell homeostasis via a Bim/Bcl-2 axis. Cell Death Dis 2012, 3:e270. 10.1038/cddis.2012.9.
34. Mellor A.L., Munn D.H. Physiologic control of the functional status of Foxp3+ regulatory T cells. J Immunol 2011, 186(8):4535-4540.
35. Esposito M., Ruffini F., Bergami A., Garzetti L., Borsellino G., Battistini L., et al. IL-17 and IFN-gamma-secreting Foxp3+ T cells infiltrate the target tissue in experimental autoimmunity. J Immunol 2010, 185(12):7467-7473.
36. O'Connor R.A., Leech M.D., Suffner J., Hammerling G.J., Anderton S.M. Myelin-reactive, TGF-beta-induced regulatory T cells can be programmed to develop Th1-like effector function but remain less proinflammatory than myelin-reactive Th1 effectors and can suppress pathogenic T cell clonal expansion in vivo. J Immunol 2010, 185(12):7235-7243.
37. Zhou X., Bailey-Bucktrout S.L., Jeker L.T., Penaranda C., Martínez-Llordella M., Ashby M., et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol 2009, 10:1000-1007.
38. + Treg cell number and acquisition of effector cell phenotype during lethal infection. Immunity 2009, 31:772-786.
39. Duarte J.H., Zelenay S., Bergman M.L., Martins A.C., Demengeot J. Natural Treg cells spontaneously differentiate into pathogenic helper cells in lymphopenic conditions. Eur J Immunol 2009, 39:948-955.
40. Vokaer B., Van Rompaey N., Lemaître P.H., Lhommé F., Kubjak C., Benghiat F.S., et al. Critical role of regulatory T cells in Th17-mediated minor antigen-disparate rejection. J Immunol 2010, 185(6):3417-3425.
41. Ferraris J.R., Tambutti M., Prigoshin N. Improved long-term graft function in kidney transplant recipients with donor antigen-specific hyporeactivity. Pediatr Transplant 2007, 11:139-144.
42. Reinsmoen N.L., Matas A.J. Evidence that improved late renal transplant outcome correlates with the development of in vitro donor antigen-specific hyporeactivity. Transplantation 1993, 55:1017-1023.
43. Harmon W.E., Parkman R., Lavin P.T., Grupe W.E., Ingelfinger J.R., Yunis E.J., et al. Comparison of cell-mediated lympholysis and mixed lymphocyte culture in the immunologic evaluation for renal transplantation. J Immunol 1982, 129:1573-1577.
44. Berg B., Groth C.G., Lundgren G., Magnusson G., Moller E., Ringden O. The influence of HLA-D matching on the outcome of intrafamilial kidney transplantation with special emphasis on the predictive value of the relative response in MLC. Scand J Urol Nephrol Suppl 1981, 64:46-51.
45. Ringden O., Berg B. Correlation between magnitude of MLC and kidney graft survival in intrafamilial transplantation. Tissue Antigens 1977, 10:364-372.
46. Solheim B.G., Flatmark A., Enger E., Jervell J., Thorsby E. Influence of HLA-A, -B, -C, and -D matching on the outcome of clinical kidney transplantation. Transplant Proc 1977, 9:475-478.